VT1021
Vigeo Therapeutics
['gbm']
vigeo therapeutics will present new clinical and immune profiling data from ph i/ii expansion study in gbm patient... 
Vigeo is a clinical stage oncology company targeting tumors with high levels of CD36 and CD47 expression